Abstract
Much progress has been made over the past 10 years with regard to development of a vaccine active against HPV. Successful protection has been achieved in animal models using species-specific papillomaviruses; however, HPV diversity may delay the development of successful HPV vaccines, especially those designed as therapeutic vaccines for the treatment of HPV-induced carcinoma and high-grade dysplasia of the cervix. Difficulties arise with regard to assessment of efficacy of potential vaccines. The impetus for long-term studies on vaccine efficacy will initially stem from in vitro evidence of responsiveness to the vaccine. The time when a vaccine will have an impact on the prevalence of high-grade dysplasia and invasive cancer is still some way off.
| Original language | English |
|---|---|
| Pages (from-to) | 835-8 |
| Number of pages | 4 |
| Journal | Dermatologic clinics |
| Volume | 16 |
| Issue number | 4 |
| Publication status | Published - 1998 |
Keywords
- Animals
- Carcinoma, Squamous Cell
- Condylomata Acuminata
- Disease Models, Animal
- Female
- Genome, Viral
- Humans
- Immunization Schedule
- Male
- Papillomaviridae
- Papillomavirus Infections
- Papillomavirus Vaccines
- Precancerous Conditions
- Tumor Virus Infections
- Uterine Cervical Dysplasia
- Vaccination
- Viral Proteins
- Viral Vaccines